669 related articles for article (PubMed ID: 19165225)
1. p53 polymorphisms: cancer implications.
Whibley C; Pharoah PD; Hollstein M
Nat Rev Cancer; 2009 Feb; 9(2):95-107. PubMed ID: 19165225
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.
Hrstka R; Coates PJ; Vojtesek B
J Cell Mol Med; 2009 Mar; 13(3):440-53. PubMed ID: 19379143
[TBL] [Abstract][Full Text] [Related]
3. Common genetic variants in the TP53 pathway and their impact on cancer.
Barnoud T; Parris JLD; Murphy ME
J Mol Cell Biol; 2019 Jul; 11(7):578-585. PubMed ID: 31152665
[TBL] [Abstract][Full Text] [Related]
4. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
6. The Enigma of p53.
Lozano G
Cold Spring Harb Symp Quant Biol; 2016; 81():37-40. PubMed ID: 27932563
[TBL] [Abstract][Full Text] [Related]
7. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
8. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.
Naccarati A; Polakova V; Pardini B; Vodickova L; Hemminki K; Kumar R; Vodicka P
Mutagenesis; 2012 Mar; 27(2):211-8. PubMed ID: 22294769
[TBL] [Abstract][Full Text] [Related]
9. The importance of p53 pathway genetics in inherited and somatic cancer genomes.
Stracquadanio G; Wang X; Wallace MD; Grawenda AM; Zhang P; Hewitt J; Zeron-Medina J; Castro-Giner F; Tomlinson IP; Goding CR; Cygan KJ; Fairbrother WG; Thomas LF; Sætrom P; Gemignani F; Landi S; Schuster-Böckler B; Bell DA; Bond GL
Nat Rev Cancer; 2016 Apr; 16(4):251-65. PubMed ID: 27009395
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
11. p53 and human cancer: the first ten thousand mutations.
Hainaut P; Hollstein M
Adv Cancer Res; 2000; 77():81-137. PubMed ID: 10549356
[No Abstract] [Full Text] [Related]
12. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
15. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
16. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.
Bond GL; Levine AJ
Oncogene; 2007 Feb; 26(9):1317-23. PubMed ID: 17322917
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.
Khan SA; Idrees K; Forslund A; Zeng Z; Rosenberg S; Pincas H; Barany F; Offit K; Laquaglia MP; Paty PB
J Surg Oncol; 2008 Jun; 97(7):621-5. PubMed ID: 18381604
[TBL] [Abstract][Full Text] [Related]
18. Shaping genetic alterations in human cancer: the p53 mutation paradigm.
Soussi T; Wiman KG
Cancer Cell; 2007 Oct; 12(4):303-12. PubMed ID: 17936556
[TBL] [Abstract][Full Text] [Related]
19. A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.
Kotler E; Shani O; Goldfeld G; Lotan-Pompan M; Tarcic O; Gershoni A; Hopf TA; Marks DS; Oren M; Segal E
Mol Cell; 2018 Jul; 71(1):178-190.e8. PubMed ID: 29979965
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
